Immunotherapy has transformed the landscape of lung cancer treatments but despite promising outcomes, only a small fraction of patients experience substantial benefits from immune checkpoint inhibitor (ICI) therapy.

Utilizing our proprietary platform, our team has been able to identify spatial biomarkers in the context of lung cancer disease that help the further classification of patients that could benefit from ICI therapy. By examining the effect of spatial immune biomarkers in the tumor’s microenvironment, we observed the tumor’s response to ICI, and evaluated gene expression profiling data to gain insights about patients’ response.

Download our application note to learn more:

Download Now